FCGR2A and neoplasm: Optimal anti-tumour activity of mAbs targeting PD-1 was achieved by blocking the inhibitory PD-1 signal in the absence of Fc-FcγR engagement, demonstrating that anti-PD1 mAb activity is FcγR-independent (125).